News

Eyewear presentation should include planned communications that help your patients understand the value of their purchases.

Two events are changing the landscape of IOLs: the advancement and acceptance of toric IOLs and the aging of patients who have undergone previous LASIK so that they now need cataract surgery.

The author reflects, lightheartedly, on our overuse of cliches.

While practices pride themselves on the quality of care they deliver, many of those same practices get low marks for their quality of caring.

No single intervention for inflammatory thyroid eye disease currently provides a cure.

Femtosecond lasers are gaining attention in the ophthalmic arena because of their ability to bring the precision of refractive surgery to cataract removal and IOL implantation.

Approaches to wound modulation after filtration surgery have not changed much over the past 20 years.

Whether you are building a new dispensary or remodeling an existing one, lighting is a critical design element.

Corneal collagen crosslinking is an effective treatment for improving uncorrected distance visual acuity, corrected distance visual acuity, and average and maximum K values.

Celebrating its 10th anniversary, the ARVO AFER provides ongoing support for a broad array of educational initiatives designed to enhance the conduct and dissemination of eye research.

Throughout his career, Robert H. Osher, MD, has been drawing large numbers of attendees at the major ophthalmic conferences to his presentations.

Having a strong knowledge base of expected outcomes with a multifocal full-optic diffractive IOL will facilitate counseling prospective surgical candidates.

Typical demyelinating optic neuritis is diagnosed by first localizing the problem.

Simultaneous topography-guided partial PRK with cornea collagen crosslinking offers a safe and effective approach for normalizing the cornea and enhancing visual function in eyes with ectatic conditions.

All phakic IOLs provide excellent predictability and efficacy along with the benefit of rapid visual recovery, but the posterior and anterior chamber models each have their own pros and cons.

A new model of ocular inflammation, an endotoxin-induced uveitis (EIU) model, has been validated by Iris Pharma, according to the company.

We may know within 6 to 10 months the results of the FDA?s review of Regeneron Pharmaceuticals? biologics license application (BLA) related to a fusion protein (VEGF Trap-Eye) for the treatment of neovascular age-related macular degeneration (AMD). If the review is favorable, use of the fusion protein ultimately could mean fewer injections per year for patients being treated for the disease.

How are you observing World Glaucoma Week this week? Eye-care institutions and local patient support groups worldwide are marking the week with awareness and educational events.

ISTA Pharmaceuticals has asked the FDA not to give tentative or final approval of any abbreviated new drug application for bromfenac sodium ophthalmic solution 0.09% that uses the labeling for the company?s discontinued twice-daily brand (Xibrom) or omits any portion of the label for its once-daily brand (Bromday) relating to the once-daily dosing.

If your practice employs opticians, nurses, occupational therapists, physical therapists, or others who teach people who are visually impaired, they may be interested in a new online course from Lighthouse International.

You now can browse high-resolution images, order, and track your REM Eyewear orders through the VisionWeb portal, www.visionweb.com, because REM Eyewear has joined the VisionWeb network of suppliers.

You have until April 1 to apply for Prevent Blindness America?s Eighth Annual Investigator Awards.

Make sure your patients know about Bausch + Lomb?s voluntary recall of all lots of an eye drop (Soothe Xtra Protection [XP]).

Carl Zeiss Meditec has opened its Center for Application and Research (CARIn) near the company?s 14-year-old sales and service company in Bangalore, India, in an effort to strengthen its presence in high-growth markets and target its investments in research and development projects.

The FDA has granted Ocular Systems Inc. (OS) 501(K) clearance to market its human corneal endothelium delivery instrument, the EndoSerter. For use during endothlelial keratoplasty, this instrument delivers a corneal endothelail allograft less than or equal to 8.5 mm in diameter and less than or equal to 175 micrograms in central thickness through a single 4-mm incision.

A proprietary fluorescein sodium and lissamine green dye combination has shown favorable results for evaluating the ocular surface.

The mandatory implementation of electronic health records looms in 2014 for health-care professionals and hospital providers.

While U.S. ophthalmologists continue to await FDA approval of the dual-optic accommodating IOL, accumulating data from a number of investigations are providing evidence about the long-term performance of this novel presbyopia-correcting implant technology.

A newer form of endothelial keratoplasty - DMEK - provides better visual and refractive outcomes compared with Descemet's stripping automated endothelial keratoplasty.

In young patients who present with low-to-moderate myopia, minimal astigmatism, and excellent optics, there is no doubt that wavefront-guided LASIK with femtosecond laser flap creation is the refractive surgery procedure of choice.